YDES YD Bio Limited
Fundamentals / CIK 0002011674 / USDYD Bio Limited reported $597K in revenue and a net loss of $8.31M for the fiscal year ended December 31, 2025 (up 16.9% year over year), with a 28.1% gross margin and a -883.3% operating margin.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open YDES in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025$597K +16.9% YoY
-
Operating Income FY 2025-$5.27M -883.3% margin
-
Net Income FY 2025-$8.31M -1392.6% net margin
-
Diluted EPS FY 2025-$0.12 Split-adjusted
-
Free Cash Flow FY 2025-$8.04M -1346.6% FCF margin
-
Cash & ST Investments Dec 31, 2025$6.01M Total debt: $14K
Annual revenue and net income
3 fiscal years (2023 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Revenue | $597K | $510K | $350K |
| Cost of Revenue | $429K | $355K | $197K |
| Gross Profit | $167K | $155K | $153K |
| Research & Development | $1.60M | $491K | -- |
| Selling, General & Admin | $3.83M | $1.13M | $161K |
| Total Operating Expenses | $5.44M | $1.62M | $163K |
| Operating Income | -$5.27M | -$1.46M | -$9.8K |
| EBITDA | -$5.06M | -$1.36M | -$7.4K |
| Interest Income | $80K | $12K | $290 |
| Interest Expense | -- | $772 | $2.1K |
| Income Before Tax | -$8.31M | -$1.39M | $18K |
| Income Tax Expense | -$1.5K | $25K | $4.1K |
| Net Income | -$8.31M | -$1.41M | $14K |
| Basic EPS | -$0.12 | -$0.02 | $0.00 |
| Diluted EPS | -$0.12 | -$0.02 | $0.00 |
| Basic Shares Outstanding | 66.7M | 64.7M | 64.7M |
| Diluted Shares Outstanding | 66.7M | 64.7M | 64.7M |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 |
|---|---|---|
| Cash & Cash Equivalents | $6.01M | $3.13M |
| Cash & Short-Term Investments | $6.01M | $3.13M |
| Accounts Receivable, Net | $167K | $87K |
| Inventory | $1.88M | $37K |
| Total Current Assets | $9.67M | $3.47M |
| Property, Plant & Equipment, Net | $59K | $64K |
| Intangible Assets | $2.61M | $2.68M |
| Total Non-Current Assets | $4.11M | $3.40M |
| Total Assets | $13.78M | $6.86M |
| Accounts Payable | $413K | $27K |
| Deferred Revenue (Current) | $30K | $28K |
| Total Current Liabilities | $1.64M | $263K |
| Long-Term Debt | $6.8K | -- |
| Total Non-Current Liabilities | $14.99M | $11K |
| Total Liabilities | $16.64M | $274K |
| Total Debt (incl. Leases) | $14K | $22K |
| Common Stock | $7.1K | $6.5K |
| Retained Earnings | -$10.24M | -$1.93M |
| Accumulated Other Comp. Income | $214K | $45K |
| Total Stockholders' Equity | -$2.86M | $6.59M |
| Total Equity | -$2.86M | $6.59M |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash & Cash Equivalents | $6.01M | $3.13M |
| Cash & Short-Term Investments | $6.01M | $3.13M |
| Accounts Receivable, Net | $167K | $87K |
| Inventory | $1.88M | $37K |
| Total Current Assets | $9.67M | $3.47M |
| Property, Plant & Equipment, Net | $59K | $64K |
| Intangible Assets | $2.61M | $2.68M |
| Total Non-Current Assets | $4.11M | $3.40M |
| Total Assets | $13.78M | $6.86M |
| Accounts Payable | $413K | $27K |
| Deferred Revenue (Current) | $30K | $28K |
| Total Current Liabilities | $1.64M | $263K |
| Long-Term Debt | $6.8K | -- |
| Total Non-Current Liabilities | $14.99M | $11K |
| Total Liabilities | $16.64M | $274K |
| Total Debt (incl. Leases) | $14K | $22K |
| Common Stock | $7.1K | $6.5K |
| Retained Earnings | -$10.24M | -$1.93M |
| Accumulated Other Comp. Income | $214K | $45K |
| Total Stockholders' Equity | -$2.86M | $6.59M |
| Total Equity | -$2.86M | $6.59M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Net Income | -$8.31M | -$1.41M | $14K |
| Depreciation & Amortization | $210K | $105K | $2.5K |
| Change in Receivables | -$84K | $6.3K | -$64K |
| Change in Inventory | -$1.84M | $29K | -$31K |
| Operating Cash Flow | -$6.60M | -$1.22M | -$56K |
| Capital Expenditure | -$1.44M | -$75K | -$290 |
| Free Cash Flow | -$8.04M | -$1.30M | -$56K |
| Investing Cash Flow | -$1.44M | -$2.90M | -$290 |
| Common Stock Issued | $13.20M | $7.55M | -- |
| Financing Cash Flow | $10.87M | $7.11M | $114K |
| Net Change in Cash | $2.88M | $3.05M | $57K |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Gross Margin | 28.1% | 30.4% | 43.8% |
| Operating Margin | -883.3% | -286.5% | -2.8% |
| Net Profit Margin | -1392.6% | -276.6% | 3.9% |
| Return on Equity (ROE) | -- | -21.4% | -- |
| Return on Assets (ROA) | -60.3% | -20.6% | -- |
| Current Ratio | 5.88x | 13.18x | -- |
| Quick Ratio | 4.74x | 13.04x | -- |
| Debt to Equity | -- | 0.00x | -- |
| Revenue Growth (YoY) | +16.9% | +45.8% | -- |
| Gross Profit Growth (YoY) | +7.8% | +1.2% | -- |
| Net Income Growth (YoY) | -- | -10509.7% | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.